38. Humblet V, Lapidus R, Williams LR, Tsukamoto T, Rojas C, Majer P, Hin B, Ohnishi S,
De Grand AM, Zaheer A, Renze JT, Nakayama A, Slusher BS, Frangioni JV (2005) Highaffinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of
prostate-specific membrane antigen. Mol Imaging 4(4):448–462
39. Liu T, Wu LY, Kazak M, Berkman CE (2008) Cell-surface labeling and internalization by a
fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68(9):955–964
40. Liu T, Wu LY, Hopkins MR, Choi JK, Berkman CE (2010) A targeted low molecular weight
near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 20(23):7124–7126
41. Baranski AC, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, Simpfendörfer T,
Teber D, Maier-Hein L, Hadaschik B, Haberkorn U, Eder M, Kopka K (2018) PSMA-11derived dual-labeled PSMA inhibitors for preoperative PET imaging and precise fluorescenceguided surgery of prostate cancer. J Nucl Med 59(4):639–645
42. Kennedy MD, Jallad KN, Thompson DH, Ben-Amotz D, Low PS (2003) Optical imaging of
metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 8(4):636–641
43. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A,
de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS, Ntziachristos V (2011) Intraoperative
tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first
in-human results. Nat Med 17(10):1315–1319
44. Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM,
Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ (2010) Selective visualization of
cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer
Res 70(9):3618–3627
45. Zhang H, Fan J, Wang J, Dou B, Zhou F, Cao J, Qu J, Cao Z, Zhao W, Peng X (2013)
Fluorescence discrimination of cancer from inflammation by molecular response to COX-2
enzymes. J Am Chem Soc 135(46):17469–17475
46. Krall N, Pretto F, Decurtins W, Bernardes GJ, Supuran CT, Neri D (2014) A small-molecule
drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem
Int Ed Engl 53(16):4231–4235
47. Krall N, Pretto F, Neri D (2014) A bivalent small molecule-drug conjugate directed against
carbonic anhydrase IX can elicit complete tumour regression in mice. Chem Sci 5:3640–3644
48. Chenouard N, Smal I, de Chaumont F, Maška M, Sbalzarini IF, Gong Y, Cardinale J,
Carthel C, Coraluppi S, Winter M, Cohen AR, Godinez WJ, Rohr K, Kalaidzidis Y,
Liang L, Duncan J, Shen H, Xu Y, Magnusson KE, Jaldén J, Blau HM, Paul-Gilloteaux P,
Roudot P, Kervrann C, Waharte F, Tinevez JY, Shorte SL, Willemse J, Celler K, van Wezel
GP, Dan HW, Tsai YS, Ortiz de Solórzano C, Olivo-Marin JC, Meijering E (2014)
Nat Methods 11(3):281–289
49. Xie W, Deng Y, Wang K, Yang X, Luo Q (2014) Reweighted L1 regularization for restraining
artifacts in FMT reconstruction images with limited measurements. Opt Lett 39
(14):4148–4151
50. Qin CH, Feng JC, Zhu SP, Ma XB, Zhong JH, Wu P, Jin ZY, Tian J (2014) Recent advances
in bioluminescence tomography: methodology and system as well as application. Laser
Photonics Revs 8(1):94–114
51. Wang K, Wang Q, Luo Q, Yang X (2015) Fluorescence molecular tomography in the second
near-infrared window. Opt Express 23(10):12669–12679
52. Leng CC, Tian J (2015) Mathematical method in optical molecular imaging. Sci China Inf Sci
58(3):1–13
53. Zhang S, Wang K, Liu HB, Leng CC, Gao Y, Tian J (2017) Reconstruction method for in vivo
bioluminescence tomography based on the split Bregman iterative and surrogate functions.
Mol Imaging Biol 19(2):245–255
54. Fan-Minogue H, Cao Z, Paulmurugan R, Chan CT, Massoud TF, Felsher DW, Gambhir SS
(2010) Noninvasive molecular imaging of c-Myc activation in living mice. Proc Natl Acad Sci
U S A 107(36):15892–15897
Fluorescence Molecular Imaging of Medicinal Chemistry in Cancer
27
De Grand AM, Zaheer A, Renze JT, Nakayama A, Slusher BS, Frangioni JV (2005) Highaffinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of
prostate-specific membrane antigen. Mol Imaging 4(4):448–462
39. Liu T, Wu LY, Kazak M, Berkman CE (2008) Cell-surface labeling and internalization by a
fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68(9):955–964
40. Liu T, Wu LY, Hopkins MR, Choi JK, Berkman CE (2010) A targeted low molecular weight
near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 20(23):7124–7126
41. Baranski AC, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, Simpfendörfer T,
Teber D, Maier-Hein L, Hadaschik B, Haberkorn U, Eder M, Kopka K (2018) PSMA-11derived dual-labeled PSMA inhibitors for preoperative PET imaging and precise fluorescenceguided surgery of prostate cancer. J Nucl Med 59(4):639–645
42. Kennedy MD, Jallad KN, Thompson DH, Ben-Amotz D, Low PS (2003) Optical imaging of
metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 8(4):636–641
43. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A,
de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS, Ntziachristos V (2011) Intraoperative
tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first
in-human results. Nat Med 17(10):1315–1319
44. Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM,
Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ (2010) Selective visualization of
cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer
Res 70(9):3618–3627
45. Zhang H, Fan J, Wang J, Dou B, Zhou F, Cao J, Qu J, Cao Z, Zhao W, Peng X (2013)
Fluorescence discrimination of cancer from inflammation by molecular response to COX-2
enzymes. J Am Chem Soc 135(46):17469–17475
46. Krall N, Pretto F, Decurtins W, Bernardes GJ, Supuran CT, Neri D (2014) A small-molecule
drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem
Int Ed Engl 53(16):4231–4235
47. Krall N, Pretto F, Neri D (2014) A bivalent small molecule-drug conjugate directed against
carbonic anhydrase IX can elicit complete tumour regression in mice. Chem Sci 5:3640–3644
48. Chenouard N, Smal I, de Chaumont F, Maška M, Sbalzarini IF, Gong Y, Cardinale J,
Carthel C, Coraluppi S, Winter M, Cohen AR, Godinez WJ, Rohr K, Kalaidzidis Y,
Liang L, Duncan J, Shen H, Xu Y, Magnusson KE, Jaldén J, Blau HM, Paul-Gilloteaux P,
Roudot P, Kervrann C, Waharte F, Tinevez JY, Shorte SL, Willemse J, Celler K, van Wezel
GP, Dan HW, Tsai YS, Ortiz de Solórzano C, Olivo-Marin JC, Meijering E (2014)
Nat Methods 11(3):281–289
49. Xie W, Deng Y, Wang K, Yang X, Luo Q (2014) Reweighted L1 regularization for restraining
artifacts in FMT reconstruction images with limited measurements. Opt Lett 39
(14):4148–4151
50. Qin CH, Feng JC, Zhu SP, Ma XB, Zhong JH, Wu P, Jin ZY, Tian J (2014) Recent advances
in bioluminescence tomography: methodology and system as well as application. Laser
Photonics Revs 8(1):94–114
51. Wang K, Wang Q, Luo Q, Yang X (2015) Fluorescence molecular tomography in the second
near-infrared window. Opt Express 23(10):12669–12679
52. Leng CC, Tian J (2015) Mathematical method in optical molecular imaging. Sci China Inf Sci
58(3):1–13
53. Zhang S, Wang K, Liu HB, Leng CC, Gao Y, Tian J (2017) Reconstruction method for in vivo
bioluminescence tomography based on the split Bregman iterative and surrogate functions.
Mol Imaging Biol 19(2):245–255
54. Fan-Minogue H, Cao Z, Paulmurugan R, Chan CT, Massoud TF, Felsher DW, Gambhir SS
(2010) Noninvasive molecular imaging of c-Myc activation in living mice. Proc Natl Acad Sci
U S A 107(36):15892–15897
Fluorescence Molecular Imaging of Medicinal Chemistry in Cancer
27